

# Acasti Pharma Inc

14:05 04 Nov 2019

## Acasti Pharma inks krill oil supply deal with Aker BioMarine to scale up production of its drug candidate CaPre

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) has partnered with Aker BioMarine for a two-year supply of krill oil, the primary ingredient in the production of its hypertriglyceridemia drug candidate CaPre.

The fixed-price supply agreement secures an adequate supply of raw krill oil through at least mid-2021, as the company ramps up production of the drug to build future inventory for commercial launch.

Shares of Acasti traded 4.3% higher at C\$2.68 on the TSXV on Monday and 5.2% higher at US\$2.03 on OTC Markets.

"We have built a state-of-the-art manufacturing operation for CaPre, and it is important for us to continue to maintain long-term relationships with the highest quality suppliers across the entire supply chain, in order to ensure continuous operations and delivery of CaPre according to plan," Acasti COO and Chief Scientific Officer Pierre Lemieux said in a statement. "Aker BioMarine produces high quality krill oil, which is sustainably harvested and has been certified by the Marine Stewardship Council."

### READ: Acasti Pharma on pace to release Phase 3 trial results of lead drug candidate CaPre in December

The companies have also agreed to contemplate future commercial collaborations, Lemieux said.

"Acasti, with its novel drug product CaPre, represents an exciting growth opportunity for our two organizations," Tim de Haas, Aker EVP of human health & nutrition, said in a statement. "We are pleased to partner with Acasti to support commercialization of the first ever, krill oil-based, prescription drug product, which we believe has the potential to become the best-in-class omega-3 therapeutic for the management of cardiometabolic disorders. We look forward to working with their team on future supply initiatives."

CaPre is an omega-3 phospholipid designed to combat high levels of triglycerides, or fatty molecules, as a treatment for hypertriglyceridemia, a metabolic condition that contributes to increased risk of cardiovascular disease and pancreatitis.

—Updated to include stock movement—


Contact Andrew Kessel at [andrew.kessel@proactiveinvestors.com](mailto:andrew.kessel@proactiveinvestors.com)

Follow him on Twitter @andrew\_kessel

**Price:** 0.96

**Market Cap:** \$88.79 m

#### 1 Year Share Price Graph



#### Share Information

**Code:** ACST

**Listing:** TSX-V

52 week	High	Low
	4.05	0.35

**Sector:** Pharma & Biotech

**Website:** [www.acastipharma.com](http://www.acastipharma.com)

#### Company Synopsis:

Acasti is a biopharmaceutical innovator focused on the research, development and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. Omega-3 fatty acids have extensive clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia.

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Acasti Pharma Inc named herein, including the promotion by the Company of Acasti Pharma Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).